Application of quercetin in preparation of products for treating and / or improving obesity and metabolism

By reshaping the intestinal flora through quercetin, the metabolite of Akkermansiamuciniphila is used to upregulate CYP8B1 protein, improve the bile acid level, and activate FXR, solving the limitations of existing obesity treatment methods and achieving obesity and effective intervention and improvement of metabolic disorders.

CN118903104APending Publication Date: 2024-11-08ZHEJIANG UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411106823.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There are limitations in the existing treatment methods for obesity, including difficulty in persisting in increased exercise or diet control, adverse reactions in drug intervention, limited scope of bariatric surgery, and lack of stable, effective and safe treatment strategies.

Method used

Quercetin as a natural polyphenol, by reshaping the intestinal microbiota structure, especially significantly enriching the probiotic Akkermansiamuciniphila, interfering with obesity and metabolic disorders, and upregulating CYP8B1 protein in the liver through its metabolite indole-3-lactic acid , promote the conversion of cholesterol to cholic acid, improve the level of bile acid in serum, activate the bile acid receptor FXR in adipose tissue, regulate inflammatory factors and key genes of lipid metabolism, and inhibit excessive fat deposition.

Benefits of technology

Quercetin intervention effectively improves obesity and related metabolic diseases. Through the metabolite of Akkermansia muciniphila, indole-3-lactic acid, the metabolite of Akkermansia muciniphila, significantly improves the bile acid level in serum, inhibits excessive fat deposition, and confirms its therapeutic and improved effect in obese mouse models. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903104A_ABST
    Figure CN118903104A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, and discloses application of quercetin to preparation of products for treating and / or improving obesity and metabolism or application of quercetin to preparation of products for regulating and controlling reasonable deposition of body fat, the administration dosage of quercetin is 100 mg / kg, and the pharmacological effect of quercetin is verified through animal experiments; it is proved that quercetin can be used for treating and / or improving obesity and related metabolic diseases, further limiting that quercetin intervention can significantly enrich the probiotics Akkermansiamuciniphila, CYP8B1 protein expression in the liver is up-regulated in a FTO-m6A mode through metabolite indole-3-lactic acid of the probiotics Akkermansiamuciniphila, the level of cholic acid in body serum is improved, and the CYP8B1 protein expression in the liver is up-regulated in a FTO-m6A mode. The cholic acid further activates a bile acid receptor FXR in the adipose tissue so as to regulate transcription of inflammatory factors and lipid metabolism key genes, and finally excessive fat deposition is inhibited; the invention develops a new application of quercetin, provides a new choice for developing medicines, functional foods and health-care products for treating and / or improving obesity and related metabolic diseases, and is safe and free from side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and specifically to the use of quercetin in preparing products for treating and / or improving obesity and metabolism. Background Art

[0002] With the development of social economy and urbanization, the prevalence of obesity has increased dramatically worldwide, which not only seriously affects people's quality of life, but also induces multiple complications such as diabetic nephropathy, non-alcoholic fatty liver disease, cardiovascular dysfunction, reproductive system diseases, etc., and has become a major public health problem threatening human health. At present, the treatment methods for obesity include increased exercise, diet control, drug intervention, bariatric surgery, etc., but there are still certain limitations, such as increased exercise or diet control is difficult to adhere to, drug intervention is often accompanied by various adverse reactions, and bariatric surgery has a limited treatment range. Therefore, it is urgent to develop stable, effective, safe and reliable new treatment strategies to prevent, improve or treat obesity and related metabolic diseases.

[0003] As an alternative to pharmacology, plant polyphenols are being explored as a medicinal option for intervention in obesity due to their high efficiency, multi-target, multi-pathway, pure natural, pollution-free, and non-toxic side effects. Quercetin is one of the most abundant and widely distributed natural polyphenolic plant compounds in the diet. It has multiple biological activities such as antioxidant, anti-inflammatory, regulating glucose and lipid metabolism, antibacterial, and anti-tumor. It has been used in the fields of medicine, functional foods, special diets, cosmetics, etc. in many countries such as the United States, Japan, and South Korea.

[0004] Existing studies suggest that quercetin may play an important role in improving the body's metabolism, but its mechanism of action is still unclear. Whether it can be used as a new option for preparing products to treat and / or improve obesity and metabolic disorders also needs further experimental verification. Summary of the invention

[0005] 1. Technical issues to be resolved

[0006] In view of the limitations of existing treatments for obesity, the present invention explores the application of quercetin in the preparation of products for treating and / or improving obesity and metabolism, providing new options for the development of drugs, functional foods and health products for treating and / or improving obesity and related metabolic diseases.

[0007] (II) Technical solution

[0008] To achieve the above objectives, the present invention is implemented through the following technical solutions: use of quercetin in preparing products for treating and / or improving obesity and metabolism, or use of quercetin in preparing products for regulating the rational deposition of body fat.

[0009] Preferably, the dosage of quercetin is 100 mg / kg.

[0010] Preferably, the obesity and metabolic disorder are caused by a long-term high-fat diet, with the energy supply ratio of fat being 60%.

[0011] Preferably, the quercetin resists obesity and metabolic disorders by reshaping the intestinal flora structure, especially significantly enriching the probiotic Akkermansia muciniphila.

[0012] Preferably, the Akkermansia muciniphila intervention can resist obesity and metabolic disorders.

[0013] Preferably, the step of Akkermansia muciniphila exerting an anti-obesity effect comprises:

[0014] S1, Akkermansia muciniphila produces the metabolite indole-3-lactic acid;

[0015] S2, indole-3-lactic acid in FTO-m 6 Method A upregulates CYP8B1 protein levels in the liver;

[0016] S3, CYP8B1 promotes the conversion of cholesterol to bile acid in the classical pathway of bile acid metabolism in the liver, increasing the level of bile acid in serum;

[0017] S4. Bile acid regulates the transcription of inflammatory factors and key genes of lipid metabolism by activating the bile acid receptor FXR in adipose tissue, thereby inhibiting excessive fat deposition.

[0018] (III) Beneficial effects

[0019] Compared with the prior art, the present invention has the following beneficial effects: based on the high-fat diet-induced obese mouse model, it is confirmed that quercetin can be used to treat and / or improve obesity and related metabolic diseases, and its mechanism of action is deeply analyzed;

[0020] Quercetin intervention induced a significant enrichment of Akkermansia muciniphila;

[0021] Akkermansia muciniphila produces FTO-m through its metabolite indole-3-lactic acid 6 Method A upregulates the expression of CYP8B1 protein in the liver, thereby promoting the conversion of cholesterol to bile acid in the classical pathway of bile acid metabolism in the liver and increasing the level of bile acid in the body's serum;

[0022] Bile acid regulates the transcription of inflammatory factors and key genes of lipid metabolism by activating the bile acid receptor FXR in adipose tissue, ultimately inhibiting excessive fat deposition. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Schematic diagram of the effect of quercetin of the present invention on the obesity phenotype of mice;

[0024] Figure 2 Schematic diagram of the effect of quercetin of the present invention on the mouse microbiome;

[0025] Figure 3 It is a schematic diagram of the effect of Akkermansia muciniphila of the present invention on the obesity phenotype of mice;

[0026] Figure 4 It is a schematic diagram showing the result of Akkermansia muciniphila of the present invention inhibiting excessive fat deposition by increasing the level of bile acid in serum;

[0027] Figure 5 It is a schematic diagram of the results of Akkermansia muciniphila of the present invention increasing the level of bile acid in serum by up-regulating the expression of CYP8B1 in the liver;

[0028] Figure 6 The Akkermansia muciniphila of the present invention is FTO-m 6 Schematic diagram of the results of upregulating CYP8B1 expression in the liver by method A;

[0029] Figure 7 The figure is a schematic diagram of the screening and identification of indole-3-lactic acid, a metabolite of Akkermansia muciniphila according to the present invention. DETAILED DESCRIPTION

[0030] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0031] Experimental reagents: Quercetin was purchased from Sigma-Aldrich, USA; high-fat diet (Research Diet, D12492) was purchased from Shanghai Biopac Biotechnology Co., Ltd.; bile acid was purchased from Aladdin Biochemical Technology Co., Ltd.; and indole-3-lactic acid was purchased from Aladdin Biochemical Technology Co., Ltd.

[0032] Experimental animals: 7-week-old, male, wild-type C57BL / 6J mice were purchased from Shanghai Slack Co., Ltd. and housed under the following conditions: temperature 22±2°C, humidity 50±5%, and 12-h light / dark alternation.

[0033] Example 1: Quercetin can treat and / or improve obesity and metabolic disorders

[0034] 1. Experimental Design

[0035] like Figure 1 As shown in A, 48 C57BL / 6J mice were randomly divided into 4 groups after 1 week of pre-feeding: basal diet group (NCD), basal diet group plus oral gavage of 100 mg / kg quercetin (NCD+Que), high-fat diet group (HFD), and high-fat diet group plus oral gavage of 100 mg / kg quercetin (HFD+Que); the experiment lasted for 10 weeks, during which the mice had free access to food and water, and the body weight, food intake and health status of the mice were recorded every day.

[0036] 2. Glucose tolerance test (GTT)

[0037] At the 8th week of the experiment, mice were fasted overnight, weighed and their basal blood glucose was tested (0 min). Glucose (1.75 g / kg) was injected intraperitoneally according to body weight, and blood was collected from the tail vein at 15, 30, 60, 90 and 120 min after injection to measure plasma glucose levels.

[0038] 3. Insulin Tolerance Test (ITT)

[0039] At the 9th week of the experiment, mice were fasted overnight, weighed and their basal blood glucose was tested (0 min). Insulin (0.75 U / kg) was injected intraperitoneally according to their body weight, and blood was collected from the tail vein at 15, 30, 60, 90 and 120 min after injection to measure plasma glucose levels.

[0040] 4. Sampling

[0041] At the end of the experiment, the mice were fasted overnight, blood samples were collected by removing the eyeballs, and then the mice were euthanized by dislocating the neck; the body surface of the mice was thoroughly disinfected with 75% ethanol, the mouse skin was cut open, and the fat, liver, intestine and other tissues were peeled off. The soybean-sized samples were fixed in polyformaldehyde for H&E staining, and the rest were all quickly frozen in liquid nitrogen for further analysis.

[0042] 5. Experimental Results

[0043] Compared with the NCD group, the body weight of the HFD group mice increased significantly ( Figure 1 B) Adipose tissue weight increased significantly ( Figure 1 D) Fat cells become significantly larger ( Figure 1 E), with glucose intolerance ( Figure 1F, G) and insulin resistance ( Figure 1 H, I), while oral administration of quercetin could effectively reverse HFD-induced obesity-related phenotypes, confirming that quercetin has the effect of treating and / or improving obesity and metabolic disorders.

[0044] Example 2: Quercetin reshapes the intestinal flora structure of mice and significantly enriches the probiotic Akkermansiamuciniphila

[0045] 1.16S rRNA sequencing

[0046] Fresh feces of mice in each group in Example 1 were collected (8th week of the experiment, before the GTT experiment), and 16S rRNA sequencing was performed using the Illumina high-throughput sequencing platform, and then the microbial diversity, microbial composition, and phenotypic correlation analysis were analyzed on the Meiji Cloud platform.

[0047] 2. Experimental results

[0048] Principal coordinate analysis (PCoA) showed that the bacterial flora structures of each group of mice were significantly separated ( Figure 2 A); The community bar graph shows that quercetin changed the relative abundance of each microorganism at the genus level ( Figure 2 B); LDA Effect size analysis ( Figure 2 C) Joint correlation heat map ( Figure 2 D) suggests that Akkermansia muciniphila may be a key mediator of quercetin's anti-obesity effects.

[0049] Example 3: Akkermansia muciniphila can treat and / or improve obesity and metabolic disorders

[0050] 1. Experimental Design

[0051] like Figure 3 As shown in A, 36 C57BL / 6J mice were randomly divided into 3 groups after 1 week of pre-feeding: basal diet group (NCD), high-fat diet group (HFD), and high-fat diet group (HFD) and gavage for 10 9 CFU Akkermansia muciniphila live bacteria group (HFD+Am); the experiment lasted for 10 weeks, during which the mice had free access to food and water, and the weight, food intake and health status of the mice were recorded every day; Akkermansia muciniphila was purchased from the American Type Culture Collection (ATCC, BAA835).

[0052] 2. Glucose tolerance test (GTT) is the same as in Example 1.

[0053] 3. Insulin tolerance test (ITT) is the same as in Example 1.

[0054] 4. The sampling scheme is the same as in Example 1.

[0055] 5. Experimental Results

[0056] Compared with the NCD group, the body weight of the HFD group mice increased significantly ( Figure 3 B) Adipose tissue weight increased significantly ( Figure 3 D) Fat cells become significantly larger ( Figure 3 E), with glucose intolerance ( Figure 3 F, G) and insulin resistance ( Figure 3 H, I), while oral administration of live Akkermansia muciniphila bacteria could effectively reverse HFD-induced obesity-related phenotypes, confirming that Akkermansia muciniphila has the effect of treating and / or improving obesity and metabolic disorders.

[0057] Example 4: Akkermansia muciniphila inhibits excessive fat deposition by increasing serum bile acid levels

[0058] 1. Non-targeted metabolomics sequencing

[0059] The serum samples of the mice in the HFD group and HFD+Am group described in Example 3 were subjected to non-targeted metabolomics sequencing using the LC-MS platform, and then the differential metabolites between the groups were analyzed and screened on the Meigi Cloud platform.

[0060] 2. Isolation of Mouse Primary Saccharomyces Preadipocytes (SVF)

[0061] 2.1 8-week-old, male, wild-type C57BL / 6J mice were selected, killed by stretching the neck, and immersed in 75% ethanol for thorough disinfection;

[0062] 2.2 Under a sterile operating environment, cut the skin on the lower back of the mouse, quickly separate the adipose tissue in the groin, rinse it three times with sterile PBS (phosphate buffered saline) containing 5% penicillin / streptomycin double antibodies, and transfer it to a sterile culture dish; in an ultra-clean workbench, cut the adipose tissue into pieces and remove the lymphatic tissue;

[0063] 2.3 The chopped adipose tissue was transferred to a 10 mL sterile centrifuge tube, and 0.2% type II collagenase was added at a volume ratio of 1:2. The tissue was shaken and digested at 200 rpm and 37°C for 1 hour. During this period, the tissue was blown and mixed every 15 minutes until the tissue was digested into flocculent. After the digestion reaction was completed, complete culture medium (DMEM culture medium + 10% fetal bovine serum + 1% double antibody) was added at a volume ratio of 1:1 to terminate the digestion.

[0064] 2.4 The digested tissue suspension was filtered through a sterile 150-mesh nylon mesh and a sterile 200-mesh nylon mesh, the filtrate was collected, centrifuged at 1200 rpm and room temperature for 5 min, and the supernatant was discarded;

[0065] 2.5 Add sterile PBS containing 5% double antibody to resuspend the cells, centrifuge at 1200 rpm and room temperature for 5 minutes, and discard the supernatant; repeat this step once;

[0066] 2.6 Add red blood cell lysis buffer and lyse at room temperature for 1 min, centrifuge at 1200 rpm at room temperature for 5 min, and discard the supernatant;

[0067] 2.7 Add complete medium to resuspend the cells, count the cells, inoculate the cells at a density of 1×107 cells in a 10 cm cell culture dish, and culture them in a 37°C, 5% CO2 incubator;

[0068] 2.8 After 6 hours of culture, change the medium and then subculture and expand the cells according to the cell density.

[0069] 3. Experimental results

[0070] Akkermansia muciniphila colonization changed the serum metabolic profile of mice, especially significantly increasing the content of secondary bile acid, cholic acid (CA), in serum ( Figure 4 A); To verify the effect of bile acid, primary preadipocytes (SVF) of mice were isolated, and the results showed that the gradient addition of bile acid did not affect cell viability ( Figure 4 B) significantly inhibited cell adipogenic differentiation ( Figure 4 C, D); it was further found that bile acid activates the bile acid receptor FXR in adipose tissue and adipocytes ( Figure 4 E, F, G), inhibiting the expression of pro-inflammatory factors and promoting the expression of anti-inflammatory factors ( Figure 4 H, I), thereby playing an anti-obesity role.

[0071] Example 5: Akkermansia muciniphila increases serum bile acid levels by upregulating CYP8B1 expression in the liver

[0072] 1. Cell Experiment Design

[0073] like Figure 5 As shown in A, equal amounts of BHI sterile medium and Akkermansia muciniphila medium were centrifuged and the supernatant was taken. Complete medium (DMEM medium + 10% bacterial supernatant + 10% fetal bovine serum + 1% double antibody) containing 10% bacterial supernatant (BHI-Sup or Am-Sup) was prepared to treat AML12 mouse hepatocytes.

[0074] 2. Experimental results

[0075] Consistent with the in vivo results, treatment of hepatocytes with Akkermansia muciniphila culture supernatant also significantly increased bile acid levels ( Figure 5 B); Mechanism studies showed that the total cholesterol content in the liver of mice in the HFD+Am group was significantly lower than that in the HFD group ( Figure 5 C), Akkermansia muciniphila culture supernatant treatment also did not affect the total cholesterol content of hepatocytes ( Figure 5 D), indicating that the increase in bile acid content is not due to more substrate (cholesterol); the protein and mRNA expression of CYP8B1 in the liver of mice in the HFD+Am group were significantly increased compared with those in the HFD group, and treatment with Akkermansia muciniphila culture medium supernatant could also significantly increase the protein and mRNA levels of CYP8B1 in hepatocytes, indicating that Akkermansia muciniphila promotes the conversion of cholesterol to bile acid by upregulating CYP8B1 expression.

[0076] Example 6: Akkermansia muciniphila with FTO-m 6 A way to upregulate CYP8B1 expression in the liver

[0077] 1. Dot blot

[0078] 1.1 mRNA denaturation: Take 100 ng mRNA, heat at 65℃ for 5 min, and then quickly put it on ice;

[0079] 1.2 Sample spotting: Place the denatured mRNA sample dropwise on the nitrocellulose membrane and let it dry at room temperature;

[0080] 1.3 UV crosslinking: UV crosslinking instrument 1200J crosslinking 120s, repeat once;

[0081] 1.4 Blocking: Prepare 5% skim milk in PBST buffer and incubate on a shaker at room temperature for 1 hour;

[0082] 1.5 Primary antibody: After washing the membrane with PBST buffer for 20 min, add m 6 Antibody A, incubate overnight at 4°C on a shaker;

[0083] 1.6 Secondary antibody: After washing the membrane with PBST buffer for 20 minutes, add the secondary antibody diluted in PBST buffer and incubate on a shaker at room temperature for 1 hour;

[0084] 1.7 Development: Detection of mRNA using chemiluminescence (ELC) 6 A-level;

[0085] 1.8 Methylene blue staining: Add methylene blue staining solution, incubate on a shaker at room temperature for 10 minutes, rinse with PBST buffer and take photos.

[0086] 2. MeRIP-qPCR

[0087] 2.1 RNA fragmentation: Dilute 50 ng RNA to 100 μL with NF-water, add 1 μL RNase inhibitor, and sonicate for 30 seconds ON, 30 seconds OFF, and 10 cycles. Take 10 μL and store it at -80℃ as input sample;

[0088] 2.2m6A IP: ① Take 25μL / sample Protein G Magnetic Beads and wash twice with 250μL Reaction buffer; ② Resuspend Beads with 250μL Reaction buffer; ③ Add 0.5μL / sample m 6 A antibody, incubate at 4°C, 20 rpm for 2 h; ④ Wash Beads-m2 twice with 200 μL Reaction buffer 6 A antibody complex; ⑤ Resuspend Beads-m with 250 μL Reaction buffer 6 A antibody complex; ⑥ Beads-m 6 Add fragmented RNA (90 μL) to the A antibody complex and incubate at 4°C, 20 rpm for 4 h; ⑦ Wash with 200 μL Reaction buffer*2, Low salt buffer*2, and High salt buffer*2 in sequence; ⑧ Add the washed Beads-m 6 Add 30 μL RLT buffer to the A antibody complex, incubate at room temperature for 10 min, collect the supernatant (30 μL), repeat once, and collect a total of 60 μL supernatant; ⑨ Add 6 μL 3M sodiumacetate (1 / 10 volume), 150 μL anhydrous ethanol (2.5 times volume), and 1 μL glycogen to the supernatant, and precipitate at -80°C overnight; ⑩ Centrifuge at 15000g, 4°C for 1 h, carefully discard the supernatant (be careful not to damage the RNA precipitate, which is not visible at the bottom of the tube), dry at room temperature, add 8 μL NF-water to resuspend, and put on ice for later use;

[0089] 2.3 Inversion: All IP and Input samples were inverted to DNA according to the instructions and diluted to 100uL after inversion;

[0090] 2.4qPCR: qPCR quantitative analysis of Cyp8b1 mRNA m 6 A level.

[0091] 3. Experimental results

[0092] Liver mRNA mRNA of mice in HFD+Am group 6 A Overall level ( Figure 6 A) Cyp8b1 mRNA 6 A Level( Figure 6 B) were significantly lower than those in the HFD group. Treatment with Akkermansia muciniphila culture supernatant also significantly reduced hepatocyte mRNA m 6 A Overall level ( Figure 6 D) Cyp8b1 mRNA 6 A Level( Figure 6 E); by detecting m 6 A regulatory factor protein expression, and found that the increase in the expression of the demethylase FTO led to m 6 A level was reduced; siFto was used to further verify that Akkermansiamuciniphila used FTO-m 6 Method A upregulates CYP8B1 expression.

[0093] Example 7: Screening and identification of indole-3-lactic acid, a metabolite of Akkermansia muciniphila

[0094] 1. Non-targeted metabolomics sequencing was the same as in Example 4, except that the sample was the bacterial supernatant.

[0095] 2. Dot blot is the same as in Example 6.

[0096] 3. Experimental Design

[0097] like Figure 7 As shown in F, 24 C57BL / 6J mice were randomly divided into 3 groups after 1 week of pre-feeding: basal diet group (NCD), basal diet group plus intraperitoneal injection of 20 mg / kg indole-3-lactic acid (ILA) group; the experiment lasted for 7 days, during which the mice had free access to food and water, and the body weight, food intake and health status of the mice were recorded every day.

[0098] 4. Sampling

[0099] At the end of the experiment, the mice were fasted overnight, blood samples were collected by removing the eyeballs, and then the mice were euthanized by dislocating the neck; the body surface of the mice was thoroughly disinfected with 75% ethanol, the mouse skin was cut open, the fat and liver tissues were peeled off, and they were quickly frozen in liquid nitrogen for further analysis.

[0100] 5. Experimental Results

[0101] Non-targeted metabolomics sequencing analysis based on Akkermansia muciniphila culture medium and blank culture medium ( Figure 7A, B), and combined with existing literature reports, five possible metabolites were screened out: indole-3-lactic acid, folic acid, α-ketoglutaric acid, fumaric acid and cis-aconitic acid ( Figure 7 C).

[0102] When the above metabolites were used to treat hepatocytes, only indole-3-lactic acid and α-ketoglutarate could simultaneously increase the protein expression of CYP8B1 and FTO ( Figure 7 D), and these two metabolites can significantly reduce hepatocyte mRNA m 6 A Overall level ( Figure 7 E); Indole-3-lactic acid has a better effect than α-ketoglutaric acid, so indole-3-lactic acid was selected for in vivo experimental verification ( Figure 7 F); Consistent with the in vitro experimental results, intraperitoneal injection of 20 mg / kg indole-3-lactic acid can significantly increase the bile acid content in mouse serum ( Figure 7 G) significantly up-regulated the protein expression of CYP8B1 and FTO in the liver ( Figure 7 H), significantly reduced liver mRNA m 6 A Overall level ( Figure 7 I); Similarly, siFto was used to further verify that indole-3-lactic acid was also produced by FTO-m 6 Mode A upregulates CYP8B1 expression, indicating that indole-3-lactic acid is a key metabolite of Akkermansia muciniphila.

[0103] Figure 1 In the figure, (A) Schematic diagram of quercetin intervention in mice, (B) weight change curve of mice, (C) average daily food intake of mice, (D) adipose tissue weight of mice, (E) H&E staining of adipose tissue of mice, (FG) glucose tolerance test (GTT) of mice, (HI) insulin resistance test (ITT) of mice;

[0104] Figure 2 In the figure, (A) principal coordinate analysis (PCoA), (B) relative abundance of each microorganism at the genus level, (C) LDA value distribution bar graph of microbial differential genera, (D) heat map of the correlation between microbial differential genera and obesity indicators;

[0105] Figure 3 In the figure, (A) Schematic diagram of mouse experiment with Akkermansia muciniphila intervention, (B) mouse body weight change curve, (C) mouse average daily food intake, (D) mouse adipose tissue weight, (E) mouse adipose tissue H&E staining, (FG) mouse glucose tolerance test (GTT), (HI) mouse insulin resistance test (ITT);

[0106] Figure 4In the figure, (A) differential metabolites in mouse serum induced by Akkermansia muciniphila colonization, (B) cell viability of primary adipocytes, (C) mRNA levels of key genes of lipid metabolism in primary adipocytes, (D) Bodipy / Hochest staining of primary adipocytes, (E) mRNA levels of bile acid receptors in mouse adipose tissue, (F) mRNA levels of bile acid receptors in primary adipocytes, (G) Bodipy / Hochest staining of primary adipocytes, (H) mRNA levels of inflammatory factors in mouse adipose tissue, (I) mRNA levels of inflammatory factors in primary adipocytes;

[0107] Figure 5 In the figure, (A) Schematic diagram of the experiment of treating hepatocytes with Akkermansia muciniphila, (B) bile acid content in hepatocyte culture medium, (C) total cholesterol content in mouse liver, (D) total cholesterol content in hepatocytes, (E) protein level of CYP8B1 in mouse liver, (F) protein level of CYP8B1 in hepatocytes, (G) mRNA level of Cyp8b1 in mouse liver, (H) mRNA level of Cyp8b1 in hepatocytes;

[0108] Figure 6 (A) Mouse liver mRNA m 6 A) Total level, (B) Cyp8b1 mRNA mRNA in mouse liver 6 A level, (C) m 6 A) protein level of regulatory factor, (D) hepatocyte mRNA m 6 A) Overall level, (E) Cyp8b1 mRNA m 6 A level, (F) FTO protein level in hepatocytes, (G) Cyp8b1 mRNA level in hepatocytes (verifying the mediating role of FTO);

[0109] Figure 7 Figure 2. (A) Volcano plot of metabolites in Akkermansia muciniphila culture medium, (B) KEGG enrichment analysis of Akkermansia muciniphila metabolites, (C) List of five predicted metabolites, (D) Protein levels of CYP8B1 and FTO in hepatocytes treated with the five metabolites, (E) mRNA levels of hepatocytes treated with α-ketoglutarate (αKG) and indole-3-lactic acid (ILA). 6 A) Overall level, (F) Schematic diagram of mouse experiment with indole-3-lactic acid intervention, (G) Bile acid content in mouse serum, (H) Protein levels of CYP8B1 and FTO in mouse liver, (I) mRNA mRNA in mouse liver 6A) Total level, (J) Cyp8b1 mRNA level in hepatocytes (validating the FTO-mediated effect).

[0110] In summary, the present invention explores new uses of quercetin and provides a new option for developing drugs, functional foods and health products for treating and / or improving obesity and related metabolic diseases, which is safe and has no side effects.

[0111] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any figure mark in the claims should not be regarded as limiting the claims involved.

[0112] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. Use of quercetin in preparing products for treating and / or improving obesity and metabolism, or in preparing products for regulating the rational deposition of body fat.

2. The use of quercetin according to claim 1 in preparing a product for treating and / or improving obesity and metabolism, characterized in that: The dosage of quercetin is 100 mg / kg.

3. The use of quercetin according to claim 1 in preparing a product for treating and / or improving obesity and metabolism, characterized in that: The obesity and metabolic disorder are caused by a long-term high-fat diet, with the energy supply ratio of fat being 60%.

4. The use of quercetin according to claim 1 in preparing a product for treating and / or improving obesity and metabolism, characterized in that: The quercetin resists obesity and metabolic disorders by reshaping the intestinal flora structure, especially significantly enriching the probiotic Akkermansia muciniphila.

5. The use of quercetin according to claim 4 in preparing a product for treating and / or improving obesity and metabolism, characterized in that: The Akkermansia muciniphila intervention can combat obesity and metabolic disorders.

6. The use of quercetin according to claim 4 in preparing a product for treating and / or improving obesity and metabolism, characterized in that: The steps by which Akkermansia muciniphila exerts its anti-obesity effects include: S1, Akkermansia muciniphila produces the metabolite indole-3-lactic acid; S2, indole-3-lactic acid in FTO-m 6 Method A upregulates CYP8B1 protein levels in the liver; S3, CYP8B1 promotes the conversion of cholesterol to bile acid in the classical pathway of bile acid metabolism in the liver, increasing the level of bile acid in serum; S4. Bile acid regulates the transcription of inflammatory factors and key genes of lipid metabolism by activating the bile acid receptor FXR in adipose tissue, thereby inhibiting excessive fat deposition.

Citation Information

Cited By

  • Akkermansia muciniphila branched chain amino acid metabolism gene nifJ and application thereof in synthesis of colostrum IgA

    CN120536332A

  • Akkermansia muciniphila branched-chain amino acid metabolism gene nifJ and its application in colostrum IgA synthesis

    CN120536332B